Xeris Biopharma (NASDAQ:XERS) Insider Beth Hecht Sells 25,000 Shares of Company Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 25,000 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $10.23, for a total transaction of $255,750.00. Following the completion of the sale, the insider directly owned 1,086,130 shares in the company, valued at $11,111,109.90. This trade represents a 2.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Thursday, October 1st, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The stock was sold at an average price of $9.41, for a total transaction of $156,827.06.
• On Tuesday, September 1st, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.49, for a total value of $141,494.34.

Xeris Biopharma Trading Up 1.1%

XERS opened at $10.46 on Thursday. The stock has a market cap of $1.91 billion, a price-to-earnings ratio of -95.09 and a beta of 0.61. The stock’s 50 day moving average price is $9.40 and its 200-day moving average price is $7.55. Xeris Biopharma Holdings, Inc. has a one year low of $5.25 and a one year high of $11.41. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. The business had revenue of $92.10 million during the quarter, compared to analysts’ expectations of $90.12 million. On average, equities analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.

Institutional Trading of Xeris Biopharma

Several institutional investors and hedge funds have recently modified their holdings of XERS. Vilga Financial Planning LLC bought a new position in Xeris Biopharma in the third quarter worth approximately $10,134,000. Legal & General Group Plc bought a new stake in Xeris Biopharma during the 2nd quarter valued at $15,941,000. Walleye Capital LLC bought a new stake in Xeris Biopharma during the 2nd quarter valued at $4,841,000. Canada Pension Plan Investment Board bought a new stake in Xeris Biopharma during the 2nd quarter valued at $1,736,000. Finally, Bank of America Corp DE purchased a new stake in shares of Xeris Biopharma in the 2nd quarter worth $11,065,000. Institutional investors own 42.75% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on XERS. Wall Street Zen raised Xeris Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Leerink Partners boosted their target price on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research note on Thursday, September 10th. Finally, Barclays boosted their target price on shares of Xeris Biopharma from $12.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, October 6th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $13.20.

Xeris Biopharma Company Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.